{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:17:03Z","timestamp":1789604223979,"version":"build-2803163510"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Eosinophilic pustular folliculitis (EPF) is an uncommon skin condition that presents as follicular papules or pustules. The treatment of EPF is challenging because of the high relapse rates. This study aims to evaluate the efficacy and safety of tofacitinib as a treatment for EPF. We present three patients with refractory EPF who were successfully treated with tofacitinib at our clinic. We also conducted a literature review using the PubMed database to gain further insight into this promising therapy. Our patients were effectively treated with tofacitinib. To the best of our knowledge, only three other patients with EPF treated with Janus kinase inhibitors have been reported and reviewed: one treated with tofacitinib and two with abrocitinib. Complete remission was observed in all patients \u2013 both our patients and the patients in the other studies \u2013 with no adverse events or relapses reported during an average follow-up period of 4.3\u2005months. Tofacitinib may be an emerging alternative treatment option for patients with EPF. Larger randomized controlled studies are needed to confirm these findings.<\/jats:p>","DOI":"10.1093\/ced\/llaf053","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T11:17:16Z","timestamp":1738408636000},"page":"1196-1200","source":"Crossref","is-referenced-by-count":6,"title":["Refractory eosinophilic pustular folliculitis treated with tofacitinib: a case series and literature review"],"prefix":"10.1093","volume":"50","author":[{"given":"Qin-Xiao","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yang","family":"He","sequence":"additional","affiliation":[{"name":"Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Luo","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1098-7542","authenticated-orcid":false,"given":"Sheng","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"key":"2025052303173540400_llaf053-B1","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/1346-8138.12125","article-title":"Clinical and histopathological differential diagnosis of eosinophilic pustular folliculitis","volume":"40","author":"Fujiyama","year":"2013","journal-title":"J Dermatol"},{"key":"2025052303173540400_llaf053-B2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.coph.2019.01.002","article-title":"Therapeutic strategies for eosinophilic dermatoses","volume":"46","author":"Simon","year":"2019","journal-title":"Curr Opin Pharmacol"},{"key":"2025052303173540400_llaf053-B3","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging topical and systemic JAK inhibitors in dermatology","volume":"10","author":"Solimani","year":"2019","journal-title":"Front Immunol"},{"key":"2025052303173540400_llaf053-B4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2009.01.031","article-title":"Follicular mucinosis: clinical, histologic, and molecular remission with minocycline","volume":"62","author":"Parker","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"2025052303173540400_llaf053-B5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jaad.2006.02.034","article-title":"Eosinophilic pustular folliculitis: a 40\u2005year retrospect","volume":"55","author":"Nervi","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2025052303173540400_llaf053-B6","doi-asserted-by":"crossref","first-page":"2331785","DOI":"10.1080\/09546634.2024.2331785","article-title":"A case of generalized eosinophilic pustular folliculitis: treatment with JAK inhibitor","volume":"35","author":"Zheng","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"2025052303173540400_llaf053-B7","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/1346-8138.17284","article-title":"Two cases of eosinophilic pustular folliculitis successfully treated with abrocitinib","volume":"51","author":"Cai","year":"2024","journal-title":"J Dermatol"},{"key":"2025052303173540400_llaf053-B8","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/j.1468-3083.2010.03674.x","article-title":"Treatment of eosinophilic pustular folliculitis with ciclosporin: suppression of mRNA expression of IL-4 and IL-13","volume":"24","author":"Otsuka","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025052303173540400_llaf053-B9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjh.13519","article-title":"JAK inhibition induces silencing of T helper cytokine secretion and a profound reduction in T regulatory cells","volume":"171","author":"Keohane","year":"2015","journal-title":"Br J Haematol"},{"key":"2025052303173540400_llaf053-B10","doi-asserted-by":"crossref","first-page":"e0178563","DOI":"10.1371\/journal.pone.0178563","article-title":"Improved efficacy of allergen-specific immunotherapy by JAK inhibition in a murine model of allergic asthma","volume":"12","author":"Aguilar-Pimentel","year":"2017","journal-title":"PLOS ONE"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf053\/61723783\/llaf053.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/6\/1196\/61723783\/llaf053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/6\/1196\/61723783\/llaf053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T07:17:45Z","timestamp":1747984665000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/6\/1196\/7994559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":10,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,2,1]]},"published-print":{"date-parts":[[2025,5,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf053","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,2,1]]}}}